Status:
TERMINATED
Study Evaluating Rapamune in Patients After Kidney Transplantation
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Renal Transplantation
Eligibility:
All Genders
Brief Summary
The purpose of this study is to obtain data on the effectiveness and safety of Rapamune under everyday conditions
Eligibility Criteria
Inclusion
- Patients having received a renal allograft from a cadaveric or living donor with low or moderate risk of developing acute rejection episodes.
Exclusion
- Contraindications according to Summary of the Product Characteristics (SmPC).
Key Trial Info
Start Date :
April 1 2001
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 1 2008
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT00240214
Start Date
April 1 2001
End Date
February 1 2008
Last Update
March 14 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Multiple Cities, Germany